INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXBusiness Wire • 02/10/24
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/24/24
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with SanofiPRNewsWire • 01/23/24
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs PipelineInvestopedia • 01/23/24
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of InhibrxInvestors Business Daily • 01/23/24
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to ShareholdersBusiness Wire • 01/23/24
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipelineGlobeNewsWire • 01/23/24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BPRNewsWire • 01/23/24
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsPRNewsWire • 11/09/23
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaPRNewsWire • 11/02/23
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaPRNewsWire • 09/19/23
Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So MuchSeeking Alpha • 08/17/23
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsPRNewsWire • 08/07/23
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin DeficiencyPRNewsWire • 05/30/23
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsPRNewsWire • 05/08/23
Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?Zacks Investment Research • 05/04/23